DekaBank Deutsche Girozentrale Has $4.03 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

DekaBank Deutsche Girozentrale cut its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 21.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,211 shares of the medical research company's stock after selling 3,376 shares during the period. DekaBank Deutsche Girozentrale's holdings in Bio-Rad Laboratories were worth $4,032,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of BIO. Commonwealth Equity Services LLC acquired a new position in shares of Bio-Rad Laboratories during the first quarter valued at $731,000. Janney Montgomery Scott LLC boosted its stake in shares of Bio-Rad Laboratories by 16.8% in the 1st quarter. Janney Montgomery Scott LLC now owns 4,724 shares of the medical research company's stock valued at $1,634,000 after purchasing an additional 680 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. grew its position in shares of Bio-Rad Laboratories by 7.7% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 836 shares of the medical research company's stock worth $289,000 after buying an additional 60 shares during the period. First Pacific Advisors LP raised its stake in shares of Bio-Rad Laboratories by 2,052.5% during the first quarter. First Pacific Advisors LP now owns 104,739 shares of the medical research company's stock worth $36,226,000 after buying an additional 99,873 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its stake in Bio-Rad Laboratories by 17.2% in the first quarter. Daiwa Securities Group Inc. now owns 2,230 shares of the medical research company's stock valued at $771,000 after acquiring an additional 328 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BIO has been the subject of several recent research reports. StockNews.com cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Thursday, August 1st. Royal Bank of Canada upped their price objective on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an "outperform" rating in a report on Thursday. Wells Fargo & Company started coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an "equal weight" rating and a $340.00 target price on the stock. Finally, Citigroup upped their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a research note on Thursday. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $391.80.

Bio-Rad Laboratories Stock Up 2.9 %

Shares of NYSE BIO traded up $10.23 during mid-day trading on Friday, reaching $368.42. 284,333 shares of the company's stock were exchanged, compared to its average volume of 249,020. The company has a current ratio of 6.28, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The business has a fifty day simple moving average of $333.99 and a 200 day simple moving average of $308.47. Bio-Rad Laboratories, Inc. has a twelve month low of $262.12 and a twelve month high of $372.27. The firm has a market capitalization of $10.27 billion, a price-to-earnings ratio of -13.48 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.28 by $0.73. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.66%. The firm had revenue of $649.70 million for the quarter, compared to analyst estimates of $628.18 million. During the same quarter in the previous year, the firm posted $2.33 earnings per share. The business's revenue was up 2.8% on a year-over-year basis. As a group, equities analysts expect that Bio-Rad Laboratories, Inc. will post 9.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the company's stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the transaction, the executive vice president now owns 147 shares of the company's stock, valued at $48,582.03. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, COO Andrew J. Last sold 3,000 shares of the company's stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $329.94, for a total transaction of $989,820.00. Following the sale, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP James Barry sold 623 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares of the company's stock, valued at $48,582.03. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.06% of the company's stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.